Reig Jofre submits results note on the third quarter of 2020

REIG JOFRE closed the third quarter of 2020 with an accumulated turnover of € 170M, a growth in sales of 16% and an EBITDA of € 19M, 55% above the 2019 figure

  • After a first semester with a growth of 25% driven by the incorporation of the new Osteoarticular product portfolio, revenue reached € 54.6 million in the third quarter, 1% above 2019.
  • International growth and the sale of essential medicines compensate for the loss of income resulting from the Covid 19 crisis.
  • In the third quarter, revenues reflected the impact of the Covid 19 preventive measures, which reduced the issuance of new prescriptions

Descargue el documento completo (PDF)